

Association Between Interleukin-6 Gene Polymorphism and Severity of Coronary Artery Disease in Patients with Diabetes [Letter]

Jing Wang, Yuan Fang, Qi Zhang, Huiyan Yang

Department of Cardiovascular Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People's Republic of China

Correspondence: Huiyan Yang, Department of Cardiovascular Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People's Republic of China, Email nyfyhy@163.com

Dear editor

Recently, an original study titled “Association Between Interleukin-6 Gene Polymorphism and Severity of Coronary Artery Disease in Patients with Diabetes”¹ was published by Yao et al in the reputable journal “Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy”. Firstly, I would like to congratulate the authors and acknowledge their successful publication.

The article concludes that The IL-6-572G/C gene polymorphism is associated with the incidence and severity of coronary heart disease in patients with diabetes.

Studies have shown,² the genotypes at the – 572G/C (rs1800796) hotspot did not show any association with age, gender, obesity, diabetes, hypertension, dyslipidemia, smoking, and coronary artery status. In addition, no significant association was observed with biochemical and inflammatory markers, namely fasting blood sugar, glycosylated hemoglobin A1c, creatinine, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, IL-6, and C-reactive protein.

Studies have shown,³ This meta-analysis found that in people with COPD, Allele C of IL6-572G/C (C vs G), homozygous model (CC vs GG), dominant model (GC+CC vs GG), recessive model (CC vs GC+ GG), homozygous model CC, recessive model (CC) in the general population and Asian population The GC+CC genotype in the dominant model (GC+CC vs GG) may be a protective factor for the risk of COPD.

In addition, ethnic diversity can be a major possible reason for genetic differences with variable genotypic and phenotypic expression.

However, there are some limitations of the current study. First, this study was a retrospective study of clinical cases with some selection bias, and the sample size of this study was small, which needs to be validated by multicenter, large sample, and prospective studies in the future. Second, the relationship between the The IL-6-572G/C gene polymorphism and the incidence and severity of coronary heart disease in patients with diabetes deserves further study. Finally, long-term clinical observation of IL-6-572G/C gene may also provide more information on the prognosis of patients.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Yao H, Pang Y, Chen Y, et al. Association between interleukin-6 gene polymorphism and severity of coronary artery disease in patients with diabetes. *Diabetes Metab Syndr Obes.* 2023;16:3599–3608. doi:10.2147/DMSO.S427873
2. Zheng GH, Chen HY, Xiong SQ, Dubé M-P. Polymorphisms of –174G>C and –572G>C in the Interleukin 6 (IL-6) gene and coronary heart disease risk: a meta-analysis of 27 research studies. *PLoS One.* 2012;7(4):e34839. doi:10.1371/journal.pone.0034839

3. Xiao C. A meta-analysis of the relationship between IL-6-174G/C,-572G/C gene polymorphism and COPD susceptibility. Available form: <https://s.wanfangdata.com.cn/thesis?q=%E5%AD%A6%E4%BD%8D%E6%8E%88%E4%BA%88%E5%8D%95%E4%BD%8D%3A%22%E8%A5%BF%E5%AE%89%E5%8C%BB%E5%AD%A6%E9%99%A2%22>. Accessed 26 January 2023.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Diabetes, Metabolic Syndrome and Obesity 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Diabetes, Metabolic Syndrome and Obesity editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Diabetes, Metabolic Syndrome and Obesity

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-journal>

<https://doi.org/10.2147/DMSO.S457900>